Decoding Cryptogenic Cardioembolism
Ann Neurol 64:364-365, Meschia,J.F., 2008
Prevalence of Fabry Disease in Patients with Cryptogenic Stroke: A Prospective Study
Lancet 366:1794-1796,1754, Rolfs,A.,et al, 2006
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021
Acute Ischemic Stroke in Adolescents
Neurol 94:e158-e169, Rambaud, R.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Ischemic Stroke and Internal Carotid Artery Web
Stroke 50:e31-e34, Mc Grory, B.,et al, 2019
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Prevention of Stroke in Patients with Silent Cerebrovascular Disease
Stroke 48:e44-e71, Smith, E.E.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
J Stroke Cerebrovasc Dis 26:2976-2980, Nam, K.W.,et al, 2017
Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice
Front Neurol 7:1-16, Nouh, A.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016
Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
Stroke 47:2380-2385, Yong, J.H.E.,et al, 2016
Emerging Risk Factors for Recurrent Vascular Events in Patients with Embolic Stroke of Unertermined Source
Stroke 47:2714-2721, Ueno, Y.,et al, 2016
Lambls Excrescense Associated with Cryptogenic Stroke
Am J Case Rep 16:876-881, Chu, A.,et al, 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Cryptogenic Stroke and Underlying Atrial Fibrillation
NEJM 370:2478-2486,2532, Sanna, T.,et al, 2014
Atrial Fibrillation in Patients with Cryptogenic Stroke
NEJM 370:2467-2477,2532, Gladstone, D.J.,et al, 2014
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Aspirin for Acute Stroke of Unknown Etiology in Resourse-Limited Settings
Neurol 83:787-793, Berkowitz, A.L.,et al, 2014
Stroke and Cancer - A Complicated Relationship
J Neurol Transl Neurosci 2:1039-1051, Dearborn, J.L.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006
Closure of Patent Foramen Ovale After Cryptogenic Stroke
Lancet 368:350-352, Wrle,J., 2006
Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Practice Parameter: Recurrent Stroke with Patent Foramen Ovale and Atrial Septal Aneurysm
Neurol 62:1042-1050, Messe,S.R.,et al, 2004
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Stroke as the First Manifestation of a Concealed Pancreatic Neoplasia
Rev Neurol 38:332-335, Perez-Lazaro,C.,et al, 2004
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997
The Effect of Multiple Neuroimaging Studies on Classification, Treatment and Outcome of Acute Ischemic Stroke
Ann Int Med 124:21-26, Salerno,S.M.,et al, 1996
Transesophageal Echocardiography in Patients with Focal Cerebral Ischemia of Unknown Cause
Stroke 27:691-694, Rauh,G.,et al, 1996
Three Territory Sign
Neurol Clin Pract 9:124-128, Nouh, A.M.,et al, 2019
Cardiac Magnetic Resonance Imaging: A New Tool to Identify Cardioaortic Sources in Ischaemic Stroke
JNNP 88:31-37, Yaghi, S.,et al, 2017
D-Dimer as a Predictor of Early Neurologic Deterioration in Cryptogenic Stroke with Active Cancer
Eur J Neurol 24:205-211, Nam, K.-W.,et al, 2017
Feasibility and Diagnostic Value of Cardiovascular Magnetic Resonance Imaging after Acute Ischemic Stroke of Undetermined Origin
Stroke 48:1241-1247, Haeusler, K.G.,et al, 2017
Stroke as the Initial Manifestation of the Human Immunodeficiency Virus
Stroke 47:e60-e62, Manwani, B.,et al, 2016
Clinicopathologic Conference, Acute Ischemic Stroke, Caused by Paradoxical Embolism Through a Patent Foramen Ovale, in a Patient with the May-Thurner Syndrome and a Hypercoagulable State Due to an Occult Renal-Cell Carcinoma
NEJM 374:1671-1680, Case 13-2016, 2016
Cryptogenic Stroke
NEJM 374:2065-2074, Saver, J.L., 2016